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1. Introduction  
Natural killer (NK) cell malignancy is a heterogeneous disorder and rare, representing <1% 
of non-Hodgkin lymphomas for most of the world, except in Asia and Latin America. In 
Asia, especially, the incidence of NK-cell lymphomas is approximately 7%–10% of 
lymphomas [Au et al., 2005]. 
The pathogenesis of NK-cell malignancies has not yet been fully elucidated. In the 2008 
World Health Organization (WHO) classification of tumors of hematopoietic and 
lymphoid tissues, there are two entities associated with NK cells: mature T-cell and NK-
cell neoplasms (including chronic lymphoproliferative disorder of NK cells, aggressive 
NK-cell leukemia, and extranodal NK/T-cell lymphoma, nasal type) and NK-cell 
lymphoblastic leukemia/lymphoma, which is included provisionally in the category of 
acute leukemias of ambiguous lineage (Table 1) [Swedlow et al., 2008]. What was 
previously described as blastic NK-cell leukemia is defined as blastic plasmacytoid 
dendritic cell neoplasm in the WHO 2008 classification [Swedlow et al., 2008]. In pediatric 
patients, the four NK cell neoplasms are rare, with blastic NK-cell lymphoma being the 
most prevalent.  
 
 Acute leukemias of ambiguous lineage 
 NK-cell lymphoblastic leukemia/lymphoma 
 Mature T-cell and NK-cell neoplasms 
 Chronic lymphoproliferative disorder of NK cells 
 Aggressive NK-cell leukemia 
 Extranodal NK/T-cell lymphoma, nasal type 
Table 1. WHO classification of hematopoietic and lymphoid neoplasms associated with NK 
cells [Swerdlow et al., 2008] 
A rigorous review of the literature to date is required to adequately understand and manage 
the various pediatric NK-cell malignant entities. The clinical characteristics of pediatric cases 
with these NK-cell malignant entities defined according to the 2008 WHO classification are 
discussed in this paper and compared to adult cases. 
2. Pathology of NK-cell neoplasms in pediatric patients 
The 2008 WHO classification of tumors of hematopoietic and lymphoid tissue recognizes 
four categories of NK-cell neoplasms: NK-cell lymphoblastic leukemia/lymphoma, chronic 
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lymphoproliferative disorder of NK cells, aggressive NK-cell leukemia (ANKL), and 
extranodal NK/T-cell lymphoma, nasal type (ENKL) (Table 1). NK-cell lymphoblastic 
leukemia involves immature NK cells, while chronic lymphoblastic leukemia/lymphoma, 
chronic lymphoproliferative disorder of NK cells, and aggressive NK-cell leukemia are 
mainly neoplasms of mature NK cells. ENKL is the main neoplasm of mature NK cells. 
Among the four entities, ANKL and ENKL are associated with Epstein-Barr virus (EBV). 
2.1 NK-cell lymphoblastic leukemia/lymphoma 
NK-cell lymphoblastic leukemia/lymphoma is a very rare disease in both adults and 
children. Because of limitations in NK-cell-specific markers, it is included as acute leukemia 
of ambiguous lineage according to the WHO 2008 classification [Swerdlow et al., 2008]. This 
neoplasm has been difficult to define. CD56 is the most important and sensitive NK-cell 
marker, but CD56 is not specific for NK cells. Previously, many cases were reported as NK-
cell leukemia because of the expression of CD57 but are plasmacytoid dendritic cell 
leukemia in the WHO 2008 classification. This issue is discussed below. 
2.2 Chronic lymphoproliferative disorder of NK cells 
Chronic lymphoproliferative disorder of NK cells is rare, especially in pediatric patients. It 
occurs in adults at a median age of 60 years. This provisional entity in the WHO 2008 
classification is characterized by a persistent (>6 months) increase in peripheral blood NK 
cells (usually 2 x 109/L) without a clearly identified cause. It is very difficult to distinguish 
between neoplastic and reactive NK cells. Cells have an NK-cell phenotype: CD16+, CD56+, 
CD2–, CD7–, surface CD3 (sCD3)–, and cytoplasmic CD3 (CD3)+. Cytotoxic markers 
including T-cell-restricted intracellular antigen-1 (TIA-1), granzyme B, and granzyme M are 
positive. EBV is negative. One pediatric case has been reported from China [Kwong et al., 
1995]. CD2 was positive and CD3 was weakly positive. EBV status was not described. The 
case was a 3-year-old female who presented hepatosplenomegaly. She died 11 days after 
diagnosis because of uncontrolled disease and did not receive chemotherapy. The clinical 
course of the majority of cases with chronic lymphoproliferative disorder of NK cells shows 
a good prognosis and transformation to aggressive disease has been rarely reported [Ohno 
et al., 1998]. 
2.3 Aggressive NK-cell leukemia 
ANKL is a systemic proliferation of NK cells with primary involvement of peripheral blood 
and bone marrow, and shows a fulminant clinical course. The age distribution of ANKL 
patients has been reported to show two peaks, one at 20 years and the other at 40 years of 
age [Suzuki et al., 2004b]. The disease typically affects patients at a younger age compared to 
other NK-cell malignancies. The clinical features, and cytological and immunohistochemical 
findings of this rare pediatric NK-cell malignancy are summarized in Tables 2 and 3. EBV is 
closely associated with the pathogenesis of this disease. Latent EBV shows monoclonality 
and causes EBV-infected NK-cell lymphoproliferative disease. 
2.3.1 Diagnosis 
Patients are diagnosed with ANKL when a proliferation of large granular lymphoblasts of 
an NK-cell phenotype is found in peripheral blood and/or bone marrow exceeding 30% of 
the total nucleated cells [Suzuki et al., 2004b]. The immunophenotype of ANKL is typically 
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defined by CD2+, sCD3–, CD3ε+, and CD56+. Loss of CD7 is occasionally observed. This 
immunophenotype is almost identical to that for extranodal NK/T-cell lymphoma, except 
for CD16+. T-cell receptor (TCR) genes are in germline configuration. Some cases are CD11b+ 
and CD57–. These neoplastic cells express FAS ligand and high levels of FAS ligand can 
found in the serum of affected patients [Kato et al., 1998]. 
2.3.2 Clinical features and immunohistochemical findings in pediatric and adolescent 
patients 
To date, 19 pediatric and adolescent cases (<19 years of age) have been reported in the 
literature from 1986 to 2010. Most patients have been reported from Japan and Korea. 
Table 2 summarizes the clinical findings of these 19 pediatric cases. Median age at 
diagnosis was 14 years (range, 2–19 years). Gender distribution was equal (9 females and 
10 males), which is the same in adult patients. Acute lymphoblastic leukemia typically 
affects children at 2–6 years of age, while the median age of ANKL patients is generally 
higher. 
Pediatric ANKL patients presented acute and rapidly progressive symptomatology. The 
most common presenting symptom is fever (12/13, 92%). Hepatomegaly (10/13, 77%), 
splenomegaly (12/16, 75%), and lymphoadenopathy (6/16, 37%) are also frequently 
observed. The incidence of these symptoms is almost same as that of adult patients [Yoo et 
al., 2009]. Two patients (cases 3 and 5) presented a chronic course and spontaneous 
regression was seen and transformation to ANKL. In adult patients, transformation from 
chronic lymphoproliferative disorder of NK cells to ANKL has been rarely reported. 
Pediatric patients manifest features of chronic active EBV infection, leading to overlap with 
EBV-positive T-cell lymphoproliferative disorders [Suzuki et al., 2004a]. The clinical 
presentation of ANKL has a resemblance to EBV-associated hemophagocytic 
lymphohistiocytosis. Chronic active EBV infection occurs predominantly in children and 
young adults and the incidence of hemophagocytosis as a clinical feature is frequently 
observed in cases of pediatric ANKL. Hypersensitivity to mosquito bites is sometimes seen 
as a preceding feature of ANKL in pediatric and adolescent patients. 
This disease is typically resistant to chemotherapy and successful treatment has been 
infrequently reported. The complete response rate is below 20% and 2-year overall survival 
rate is 5% in adult patients [Suzuki, 2010; Suzuki et al., 2010]. There is insufficient data to 
interpret complete remission and overall survival rates in pediatric ANKL patients. Results 
have been unsatisfactory using combination chemotherapy regimens that are typically used 
for acute lymphoblastic leukemia or non-Hodgkin lymphoma. In adults, chemotherapy with 
L-asparaginase-containing regimens has been reported to be effective in some cases 
[Ichikawa et al., 2010]. Among pediatric ANKL cases, only two patients were reported as 
being alive and one patient died with complete remission, while 13 cases died and one (case 
15) died of graft-versus-host disease (GVHD) and infection without relapse. The median 
survival time for patients who died is 4 months. Two cases received allogeneic stem cell 
transplantation: one died due to GVHD without disease and one was alive. Chemotherapy 
with L-asparaginase-containing regimens and subsequent allogeneic stem cell 
transplantation led to prolonged survival in a few young adult patients, even when the stem 
cell transplantation was performed in patients who did not have a complete response [Ito et 
al., 2008]. Better outcome is suggested among patients who received allogeneic stem cell 
transplantation. 
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Case 
Age/ 
gender 
Fever
Hepato-
megaly
Spleno-
megaly
Lymph- 
adenopathy 
Other
sites 
Treatment Prognosis Reference 
1 6 y/M + + + +  NHL-BFM 
90/Allo-SCT 
Alive Ohnuma et 
al., 1997 
2 14 y/F + + + + Skin VCR/Dox/Cy
/CA 
Aggressive, 
died 4 mo 
Koizumi et 
al., 1986 
3 13 y/M ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
4 15 y/M ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
5 16 y/F ND ND + ND  ND ND Kawa-Ha 
et al., 1989 
6 16 y/F + + + –  ND Aggressive, 
died 32 mo 
Imamura et 
al., 1990 
7 13 y/F + + + +  ND Aggressive, 
died 26 mo 
Imamura et 
al., 1990 
8 18 y/M + + + + Lung VDS/THP-
ADR/Cy/PSL
Aggressive, 
died 4 mo 
Furuno et 
al., 1994 
9 13 y/M + + + –  PSL Aggressive, 
died 47 d 
Kaizu et 
al., 2004 
10 19 y/F + + – – HPS DHAP Aggressive, 
died 14 d 
Kohrt & 
Advani, 
2004 
11 17 y/F + + + –  COP/BLM Aggressive, 
died 1 mo 
Suzuki et 
al., 2004b 
12 12 y/M + - - + Lung DNR/Cy/VCR
/L-Asp/PSL 
Aggressive, 
died 5 mo 
Suzuki et 
al., 2004b 
13 16 y/F + + + – Kidney PSL Aggressive, 
died 1 d 
Suzuki et 
al., 2004b 
14 18 y/F + – – + Tonsil CHOP/Allo-
SCT 
Died due to 
GVHD 39 mo 
Suzuki et 
al., 2004b 
15 13 y/M – – + –  AIEOP-95 Alive, CCR 
1447 d 
Patel et al., 
2010 
16 14 y/F ND ND ND ND  ND Aggressive, 
died 1 mo 
Yoo et al., 
2009 
17 2 y/M ND ND ND ND  ND Aggressive, 
died 5 d 
Yoo et al., 
2009 
18 16 y/M ND ND ND ND  ND Aggressive, 
died 11 mo 
Yoo et al., 
2009 
19 5 y/M + + – – HPS HLH2004 Aggressive, 
died 4 mo 
Petterson 
et al., 2008 
Abbreviations: ADR, adriamycin; AIEOP-95, Associazione Italiana Ematologia Oncologia Pediatrica 95 
protocol; Allo-SCT, allogeneic stem cell transplantation; BLM, bleomycin; CA, cytarabine; CCR, clinical 
complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; COP, 
cyclophosphamide, vincristine, prednisolone; Cy, cyclophosphamide; d, days; DHAP, dexamethasone, 
high-dose cytarabine, cisplatin; Dox, doxorubicin; F, female; GVHD, graft-versus-host disease; 
HLH2004, hemophagocytic lymphohistiocytosis 2004 protocol; HPS, hemophagocytosis; L-Asp, L-
asparaginase; M, male; mo, months; ND, not determined; NHL-BFM 90, non-Hodgkin lymphoma-
Berlin-Frankfurt-Munster 90 protocol; mo, month; PSL, prednisolone; THP-ADR, pirarubicin; VCR, 
vincristine; VDS, vindesine; y, year. 
Table 2. Clinical characteristics of pediatric patients with aggressive NK leukemia 
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Yoo et al. have reported that CD7 antigen loss is frequently observed among adult ANKL 
patients and the absence of CD7 may serve as a reliable marker for the diagnosis of ANKL 
in adults [Yoo et al., 2009]. However, CD7+ is shown in 13 of 16 pediatric ANKL patients 
(Table 3). Immunophenotypic analysis of CD7 expression is therefore not useful in the 
diagnosis of ANKL in pediatric patients. EBV DNA is detected in almost all pediatric 
patients. 
 
 
Case CD2 CD3ε sCD3 CD4 CD7 CD8 CD16 CD56 CD57 EBV DNA Reference 
1 + ND – – + – – + – + Ohnuma et al., 
1997 
2 + ND – – ND – + – – + Koizumi et al., 
1986 
3 + ND – – ND – + ND ND + Kawa-Ha et al., 
1989 
4 + + – – + – – + ND + Kawa-Ha et al., 
1989 
5 + ND – – + – + + ND + Kawa-Ha et al., 
1989 
6 + ND – – + – + ND - ND Imamura et al., 
1990 
7 + ND – – + – ND + ND ND Imamura et al., 
1990 
8 + ND – – + – + ND ND + Furuno et al., 
1994 
9 + ND – ND + ND – + – + Kaizu et al., 2004 
10 ND + – ND ND ND ND + ND ND Kohrt & Advani, 
2004 
11 + ND – – + + ND + ND + Suzuki et al., 
2004b 
12 + ND – – – – + + ND + Suzuki et al., 
2004b 
13 + ND – – + – + + ND + Suzuki et al., 
2004b 
14 + – – – + – ND + - ND Suzuki et al., 
2004b 
15 – + – – – – – + ND ND Patel et al., 2010 
16 + + – – + – + + ND ND Yoo et al., 2009 
17 + + – ND + ND + + ND ND Yoo et al., 2009 
18 + + – – + – + + ND – Yoo et al., 2009 
19 + + – – – + ND + ND + Petterson et al., 
2008 
 
Abbreviations: EBV, Epstein-Barr virus; ND, not determined. 
Table 3. Phenotypic characteristics of pediatric patients with aggressive NK leukemia. Case 
numbers correspond with those in Table 2 
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2.4 Nasal and extranodal NK-cell lymphoma 
ENKL is characterized by vascular damage and destruction, prominent necrosis, a cytotoxic 
phenotype, and an association with EBV. ENKL typically presents in the nasal cavity or 
nasopharynx, with most cases having tumors localized in the upper aerodigestive tract 
(UAT) including nasal cavity, nasopharynx, oral cavity, oropharynx, and hypopharynx. 
Primary tumors that present outside the UAT, but share identical histologic features with 
the UAT disease, have also been categorized as non-nasal-type NK/T-cell lymphoma 
(NUAT-ENKL). There is clinical heterogeneity between nasal and extranasal UAT-ENKL or 
between UAT-ENKL and NUAT-ENKL [Kohrt et al., 2009; Kim et al., 2008]. Kim et al. 
reported that NUAT-ENKL had significantly higher proportions of disseminated disease, 
aggressive biologic features, and worse prognosis than UAT-ENKL [Kim et al., 2008]. In the 
UAT-ENKL group, there are differences in clinical prognostic factors between nasal UAT 
and extranasal UAT. Patients with extranasal UAT showed a higher proportion of advanced 
disease (stages III and IV on the Ann Arbor system) and regional lympohadenopathy. 
However, there did not seem to be any difference between extranasal UAT-ENKL and nasal 
UAT-ENKL with respect to survival rate. Compared to patients with UAT-ENKL (including 
both nasal and extranasal UAT ENKL), patients with NUAT-ENKL showed significantly 
higher proportions of advanced-stage disease, two or more extranodal sites, positive 
regional lymphadenopathy, presence of B symptoms, and poor Eastern Cooperative 
Oncology Group performance status. As a result of the aggressive features of NUAT-ENKL, 
survival rates were lower than those of UAT-ENKL (5-year overall survival rate: 22% versus 
41%, P <0.001) [Kim et al., 2008]. 
ENKL is rare in Western countries, but is more frequent in East Asia, and Central and South 
America [Oshimi, 1996]. It represents 3.3% of all non-Hodgkin lymphoma in Japan, 6% in 
Hong Kong, 8% in Korea, and 5% in Taiwan [Lymphoma Study Group of Japanese 
Pathologists, 2000]. ENKL is the most common lymphoma type among primary nasal-type 
lymphomas in Asian patients. The male:female ratio in approximately 3:1 and the median 
age of presentation is middle age [Ishida & Kwong, 2010]. ENKL shows onset at an older 
age than ANKL. 
2.4.1 Diagnosis 
The immunophenotype of ENKL is typically CD2+, CD56+, CD3ε+, sCD3–, CD4–, CD20–, and 
CD30–. CD56, a highly useful marker for NK cells, is not specific for ENKL and can be 
expressed in peripheral T-cell lymphomas. Occasional cases are CD7+ or CD30+. ENKL 
shares many feature with ANKL, such as the presence of azurophilic granules in the 
cytoplasm of the neoplastic cells and identical immunophenotype except for CD16 
expression. CD16 is negative in ENKL cases, but is positive in most ANKL cases [Nava & 
Jaffe, 2005]. As with ANKL, ENKL tumor cells are usually EBV positive. Cytotoxic 
molecules are positive (granzyme B, TIA-1, and perforin). Lymphomas that demonstrate a 
CD3ε+ and CD56– immunophenotype are also classified ENKL if both cytotoxic molecules 
and EBV are positive. TCR rearrangement is in the germline configuration. CD56 is a highly 
useful marker of NK cells but is not specific for ENKL. CD56 is expressed in peripheral T-
cell lymphomas, particularly those that show the gamma delta TCR configuration. 
2.4.2 Clinical features and Immunohistochemical findings in pediatric and adolescent 
patients 
In this literature review, all journals were searched from 1996 to date for ENKL cases (Tables 
4 and 5). Twenty-one pediatric cases with ENKL were reported: seven from Asia, 11 from 
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Case Age/ 
gender 
Stage 
(Ann 
Arbor) 
Fever Subtype
(primary 
site) 
Sites 
involved
Other 
signs
Treatment Prognosis Reference 
1 17 y/M IV + NUAT L/S/LN HPS mBACOD, 
2-CdA 
Aggressive, 
died 2 mo 
Kwong et al., 
1997 
2 17 y/F I – UAT 
(nasal) 
  CHOP Alive 27 mo Kwong et al., 
1997 
3 18 y/F I – UAT 
(nasal) 
  CHOP Alive 107 mo Kwong et al., 
1997 
4 16 y/F II + NUAT Cecum  CHOP Aggressive, 
died 7 mo 
Lei et al., 1997 
5 15 y/F IV + NUAT L/S/Mes
o/BM 
 – Aggressive, 
died 59 d 
Catlin et al., 
1999 
6 1 mo/M IV + NUAT L/S/BM  IFN- Aggressive, 
died 6 d 
Catlin et al., 
1999 
7 9 y/M II – NUAT Sk/LN  POG9219/
CCG1883/
HDC 
Alive, 41 mo Shaw et al., 
2001 
8 12 y/M II – NUAT M/LN  POG9219/I
CE/HDC
Alive, 15 mo Shaw et al., 
2001 
9 17 y/M IV ND NUAT Sk HPS ND Died 33 mo Ko et al., 2004 
10 17 y/M IV – NUAT L/Sk/L
N 
 GEM/IRI Aggressive, 
died 67 d 
Pol-Rodriguez 
et al., 2006 
11 17 y/F IV + NUAT LN/Sk/S
/K/P/O
HPS/H
MB 
CHOP Aggressive, 
died 3 mo 
Aydin et al., 
2007 
12 0.7 y/F I ND UAT 
(mastoid)
  POG9219 Alive Hutchinson et 
al., 2008 
13 16.3 y/M I ND UAT 
(nasal) 
  POG9219 Died Hutchinson et 
al., 2008 
14 16.3 y/F II ND UAT 
(nasal) 
Sk  POG9219 Alive Hutchinson et 
al., 2008 
15 16.6 y/M II ND UAT 
(nasal) 
  POG9219 Died Hutchinson et 
al., 2008 
16 16 y/M I – UAT 
(nasal) 
  CHOP Alive, CCR 
>24 mo 
Chang et al., 
2008 
17 12 y/F I – UAT 
(nasal) 
  CHOP/IR Alive, CCR 8 
mo 
Lee et al., 2008 
18 11 y/M IV + UAT 
(nasal) 
BM HPS – Aggressive, 
died 5 mo 
Brodkin et al., 
2008 
19 9 y/F I + UAT 
(nasophary
nx) 
 HMB CHOP ND Zhang et al., 
2009 
20 15 y/F IV + UAT 
(tonsil) 
 HPS/L
i/S 
CHOP Died 1 mo Pellier et al., 
2009 
21 4 y/M I + UAT 
(nasal) 
  CHOP Aggressive, 
died 18 d 
Miles et al., 
2010 
Abbreviations: BM, bone marrow; CCG1883, Childhood Cancer Group 1883 protocol; CCR, clinical 
complete response; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; d, days; F, 
female; GEM, gemcitabine; HDC, high-dose chemotherapy; HMB, hypersensitivity to mosquito bites; 
HPS, hemophagocytosis; ICE, ifosfamide, carboplatin, etoposide; IFN-interferon alpha; IR, irinotecan; 
K, kidney; L, lung; Li, liver; LN, lymph node; M, mastoid; mo, months; P, pancreas; POG9219, Pediatric 
Onocology Group 9219 protocol; M, male; mBACOD; bleomycin, adriamycin, cyclophosphamide, 
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vincristine, dexamethasone, methotrexate; meso, mesosalpinx; ND, not determined; NUAT; non-upper 
aerodigestive tract; O, oral; S, spleen; Sk, skin; UAT; upper aerodigestive tract; y, years; 2-CdA, 2-
chlorodeoxyadenosine. 
Table 4. Clinical characteristics of pediatric patients with extranodal NK leukemia 
 
Case CD2 CD3ε sCD3 CD4 CD7 CD8 CD16 CD56 Cytotoxic 
markers
TCR re-
arrangement
EBV 
DNA
Reference 
1 + ND – – – – – + ND ND ND Kwong et al., 
1997 
2 + ND – – – – – + ND ND ND Kwong et al., 
1997 
3 + ND – – – – – + ND ND ND Kwong et al., 
1997 
4 + – – – + –  + ND – ND Lei et al., 1997 
5 – – – – NT – – + ND NT + Catlin et al., 1999 
6 – – – + + + + + ND NT + Catlin et al., 1999 
7 + – – – – – – + ND – – Shaw et al., 2001 
8 – – – – – – – + ND ND + Shaw et al., 2001 
9 ND ND ND ND ND ND ND ND ND – + Ko et al., 2004 
10 + + + + + + + + TIA-1+ NT + Pol-Rodriguez et 
al., 2006 
11 + + ND – ND – ND – Granzym
e B+ 
– – Aydin et al., 2007 
12 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
13 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
14 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
15 ND ND ND ND ND ND ND ND ND ND ND Hutchinson et al., 
2008 
16 + + NT + + – NT – TIA-1, 
granzyme 
B+ 
+ + Chang et al., 2008 
17 NT + + NT NT NT + + NT NT – Lee et al., 2008 
18 + + + NT NT - NT + NT NT + Brodkin et al., 
2008 
19 + NT + NT + + NT – TIA-1 + – + Zhang et al., 2009 
20 + + + + + + – + ND + + Pellier et al., 2009 
21 + + NT – + + NT – TIA-1+ + + Miles et al., 2010 
Abbreviations: EBV, Epstein Barr virus; ND, not determined; NT, not tested; TCR, T-cell antigen receptor; 
TIA-1, T-cell-restricted intracellular antigen-1. 
Table 5. Phenotypic characteristics of pediatric patients with extranodal NK leukemia. Case 
numbers correspond with those in Table 4 
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US (including one with acquired disease), and one each from Turkey, South America, and 
France. In adult patients, the International Peripheral T-cell Lymphoma Project reported a 
four-fold higher relative frequency of ENKL among lymphoma in Asian countries compared 
to Western countries [Au et al., 2009]. For peripheral T-cell lymphoma, ENKL was the most 
common histology in Asian countries (range 34%–56%) except for Japan (11%) [Au et al., 
2009]. In children and adolescents, the frequency of Asian cases is the same as in adults. 
Median age is 16 years (range, 0.7–18 years excluding the infant with acquired disease) and 
the mean age is 13 years. ENKL presents at a higher age than other forms of pediatric 
leukemia/lymphoma in a similar manner to other NK-lineage leukemias/lymphomas. 
There were 11 males and 9 females (male to female ratio, 1.22:1) and male predominance has 
been reported in adults. 
Of the 21 pediatric patients, 14 patients had local disease (stage I and II) and seven had 
disseminated disease (stage III and IV) on the Ann Arbor staging system. The ratio of 
patients with UAT-ENKL as compared to those with NUAT-ENKL is 7:2 in adults and 2:1 in 
pediatric patients (Table 4). In pediatric patients, the frequency of NUAT-ENKL patients is 
higher than in adults [Oshimi et al., 2005]. In pediatric ENKL patients, about half of them 
presented UAT-ENKL: nine patients had a nasal site and three patients had an extranasal 
site, including mastoid, tonsil, and skin. UAT patients have been regarded as having no 
dissemination to other sites [Kim & Heo, 2009]. Cases 18 and 21 are therefore exceptional 
cases. They had significant hepatomegaly and lymphadenopathy. Their condition 
deteriorated progressively and lymph node biopsy and bone marrow aspiration presented 
the invasion of ENKL cells. Case 18 died after 4 days and case 20 died after 30 days from 
onset [Brodkin et al., 2008]. In adult patients, only 16% of UAT-ENKL patients are reported 
to have involvement of an extranodal site [Kim et al., 2008]. 
The proportion of pediatric NUAT-ENKL with a primary tumor outside the UAT is higher 
than that in adults. In adults, Kim et al. reported three patients with local disease (stage II) 
and six with disseminated disease (stage IV) [Kim et al., 2008]. Patients with NUAT-ENKL 
showed higher proportions of advanced-stage disease than adult patients with NUAT- 
ENKL. In pediatric patients tumor tended to disseminate. The sites involved were lymph 
node (5 cases), spleen (5 cases), lung (4 cases), bone marrow (2 cases), and skin (2 cases). The 
predominant site of adult NUAT-ENKL group is skin (37%), liver or spleen (31%), and the 
GI tract (24%). 
Hemophagocytosis (HPS) can be a complication in ENKL (2%–8% of patients) [Kim et al., 
2008]. In pediatric patients, four (1 UAT and 3 NUAT) of 20 cases were reported with HPS 
(Table 4). The frequency of HPS in pediatric patients may be higher than that of adults. 
2.4.3 Hypersensitivity to Mosquito Bite syndrome and ENKL 
Hypersensitivity to mosquito bite (HMB) syndrome is characterized by an intense skin 
reaction and systemic symptomatology such as high fever, lymphadenopathy, and 
hepatosplenomegaly. This condition has been mostly reported in Japanese children. HMB 
syndrome occurs in association with NK-cell lymphocytosis-related chronic EBV infection. 
CD4+ T cells from patients respond markedly to mosquito salivary gland extracts, and CD4+ 
T cells stimulated by mosquito bites may play a key role in the development of HMB 
syndrome and NK-cell oncogenesis. It is unclear how stimulated CD4+ T cells are involved 
in viral reactivation of viral oncogene expression in NK cells (Fig. 1) [Asada, 2007]. In the 20 
pediatric ENKL cases in this review, two cases may have exhibited HMB syndrome before 
ENKL; one from China and the other from Turkey. 
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Fig. 1. CD4+ T cells stimulated by mosquito bites may play a key role in the development of 
hypersensitivity to mosquito bites (HMB) and NK-cell oncogenesis via the induction of 
Epstein-Barr virus (EBV) reactivation and EBV-oncogene latent membrane protein 1 (LMP1) 
expression, respectively [Asada 2007] 
2.4.4 Treatment and outcome 
There remains a lack of consensus on the treatment of ENKL and there is no standard 
therapy in adults or pediatric patients. ENKL shows an aggressive clinical course with 
various clinicopathologic characteristics. Due to this clinical heterogeneity of ENKL, optimal 
treatment and prognostic factors have been difficult to determine with the conventional Ann 
Arbor staging system. NUAT-ENKL has a pathologic similarity to UAT–ENKL but is a 
clinically distinct subtype. 
2.4.4.1 Radiotherapy 
For early-stage ENKL, both UAT and NUAT, experience with radiation therapy, 
chemotherapy, and combined therapy has been reported. The largest study with 
radiotherapy or radiotherapy plus chemotherapy was reported by Kim et al. [2001]. In this 
report of 143 patients, 104 received upfront radiotherapy alone with a median dose of 50.4 
Gy (range, 20–70 Gy). Of those who received radiotherapy alone, 69% of patients achieved a 
complete response (CR), while only 8% of those who received chemotherapy prior to 
radiotherapy achieved CR [Kim et al., 2001; Korht & Advani 2009]. Huang et al. reported CR 
and 5-year overall survival (OS) rates of 100% in patients who received radiotherapy alone, 
while those who received chemotherapy (CHOP) alone had rates of 25% and 90%, 
respectively [Huang et al., 2008]. Li et al. reported overall response in 85 of 87 (97.7%) 
patients with stage I UAT-ENKL who received radiotherapy with 50–56 Gy (standard is 50 
Gy). The 5-year OS, 5-year progression-free survival (PFS), and local control rates for all 
patients were 80%, 69%, and 93%, respectively [Li et al., 2011b]. 
The dose and field of radiation in stage I or II ENKL is an important factor with respect to 
outcome. A radiation dose of at least 54 Gy is seen as being associated with better outcome. 
Comparing those who received ≥54 Gy versus <54 Gy, 5-year OS and disease-free survival 
(DFS) rates were higher with the former: 75% vs 46% and 60% vs 46%, respectively [Huang 
et al., 2008]. Systemic failure is shown in 25% to 30% of patients with stage II and II disease 
treated with radiotherapy alone. This shows the role of chemotherapy in control of clinically 
occult disease. 
2.4.4.2 Chemotherapy 
There are few studies that included patients treated with chemotherapy alone. Studies of 
chemotherapy regimens including cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) are disappointing because of high rates of refractory disease or early 
relapse: the CR rate with chemotherapy alone was <33% and 2-year DFS and OS were 23% 
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and 44%, respectively [Kim et al., 2003]. This poor prognosis with chemotherapy alone 
appears related to high P-glycoprotein (P-gp) expression in this NK-cell neoplasm. P-gp is 
associated drug efflux and treatment resistance. 
2.4.4.3 Combined modality therapy 
For the control of clinically occult early-stage disease, a combined modality therapy is 
anticipated to reduce distant failure and overall risk of relapse. In a series of 108 patients 
with early-stage ENKL receiving radiotherapy followed by chemotherapy consisting with 
cyclophosphamide, epirubicin, vincristine, prednisolone, and bleomycin [Avilés et al., 2003], 
combined therapy demonstrated high efficacy with a 92% overall response rate and 8-year 
OS of 86%. In early-stage ENKL, Guo et al. reported that patients who received CHOP 
followed by radiotherapy (45 Gy) had a CR rate of only 49% as compared to 100% for those 
who received radiotherapy prior to CHOP [Guo et al., 2008]. Li et al. reported that patients 
with early-stage UAT-ENKL (stages I and II) treated with radiotherapy or radiotherapy plus 
chemotherapy had 5-year OS and PFS rates of 72% and 65%, respectively, overall. The 
cumulative rates of 5-year systemic failure and OS, respectively, were 24% and 74% for 
combined modality therapy as compared to 28% and 70% for radiotherapy alone. There was 
no significant difference between radiotherapy alone and combined modality therapy. A 
very low incidence of cervical lymph node or CNS relapse was observed. As a result, the 
addition of chemotherapy did not significantly decrease the systemic failure rate or improve 
survival [Li et al., 2011a]. In the Japanese JCOG 0211 study [Yamaguchi et al. 2008], 27 
patients received radiotherapy (50 Gy) and reduced-dose chemotherapy (carboplatin 
etoposide, ifosfamide, and dexamethasone). The CR rate was 77% and overall response rate 
was 81%. Of the ten patients with disease recurrence, nine failed at a distant site. These 
studies demonstrate that local control using radiotherapy should precede systemic 
chemotherapy. Prospective studies are needed to clarify the role of chemotherapy. 
2.4.4.4 Advanced-stage disease 
Combined chemotherapy and radiotherapy is the most commonly used approach for 
advanced-stage disease. Due to the limited number and size of series, the efficacy of 
intensive therapy has not been demonstrated. For CHOP or m-BACOD (bleomycin, 
vincristine, dexamethasone, and methotrexate) followed by radiotherapy, the CR rate in 
patients with advanced-stage disease was 25% and median OS was 2 months as compared 
to 75% and 12 months, respectively, in those with early-stage disease [Kwong et al., 1997]. 
L-asparaginase has been reported as a novel approach for the treatment of advanced-stage 
ENKL. NK-cell tumors appear highly sensitive to L-asparaginase in vitro, as NK cells 
express low levels of asparaginase synthase. In a series of 15 patients with relapsed or 
refractory ENKL treated with L-asparaginase monotherapy, seven achieved a CR with an 
overall response rate of 87% [Jaccard et al., 2009]. Yamaguchi et al. have reported the 
efficacy of the SMILE regimen consisting with steroids, methotrexate, ifosfamide, L-
asparaginase, and etoposide. These agents are independent of the multidrug resistant 
mechanism (mediated by P-gp) in tumor cells. This phase I study included six patients with 
advanced-stage disease. The overall response rate after 2 cycles of SMILE therapy was 67%, 
with 50% achieving CR [Yamaguchi et al., 2008]. 
2.4.4.5 Stem cell transplantation 
Autologous and allogeneic stem cell transplantation (SCT) have been evaluated for 
consolidation and for relapsed or refractory disease. Suzuki et al. reported 25 CR patients 
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who received SCT and 4-year OS was 68% [Suzuki et al., 2006]. This demonstrated a 
significant benefit compared to 188 historical controls who had 4-year OS of 21%. As there 
have been few reports of SCT, the ability to define its role as therapy for relapsed or 
refractory disease remains limited. For refractory and relapsed ENKL patients, Yokoyama et 
al. reported a retrospective analysis of five cases treated with allogeneic SCT [Yokoyama et 
al., 2010]. All five patients received a myeloablative conditioning regimen (total body 
irradiation/cyclophosphamide with or without cytarabine) and survived without disease 
(median follow-up period of 1,911 days). This small case series suggests that allogeneic SCT 
might improve the outcome of advanced-stage ENKL. 
2.4.4.6 Pediatric study 
In the pediatric ENKL patients (excluding case 19 whose prognosis was not reported), eight 
of 12 patients with early-stage (stage I and II) disease including UAT and NUAT were alive 
(Table 4). Two cases were not described in detail and another two cases died within 1 year. 
The CR rate is 61%. Case 21 had nasal and right cervical lymphadenopathy and his tumor 
was not controlled; he died despite CHOP and more intensive chemotherapy. The outcome 
of pediatric early-stage patients was worse than in adults. The reason is that most cases did 
not receive radiotherapy and received chemotherapy alone, generally CHOP. 
In advanced-stage disease (stage IV), all cases died and average survival was 181 days (6 
days to 33 months). Both UAT and NUAT cases show very progressive disease and poor 
prognosis. Two cases with NUAT received high-dose chemotherapy, had complete 
remission, and were alive. Case 9 received cord blood SCT after a conditioning regimen 
consisting of total body irradiation (12 Gy), thiotepa, and cyclophosphamide, while case 10 
received autologous SCT after thiotepa and cyclophosphamide. 
There have been no large studies in pediatric patients. The largest is a report from China. 
Wang et al. reported the outcome of 37 pediatric and adolescent UAT-ENKL patients. 
Among the patients with stage I and II disease, 19 patients received primary radiotherapy 
with or without chemotherapy, and 14 patients received chemotherapy followed by 
radiotherapy. The CR rate after initial radiotherapy was 74%, which was significantly higher 
than the response rate after initial chemotherapy (17%). The median radiation dose for the 
primary tumor was 50 Gy (range, 15–60 Gy), with dose fractions of 1.8–2 Gy. They reported 
no late side effects, e.g. secondary malignancy [Wang et al., 2009]. 
2.5 Blastic plasmacytoid dendritic cell neoplasm and blastic NK-cell lymphoma 
Blastic plasmacytoid dendritic cell neoplasm (pDCL) defines leukemia/lymphoma with 
expression of CD4 and CD56 without any other lineage-specific markers. pDCL is rare and 
presents a <1% of acute leukemias and 0.7% of cutaneous lymphomas [Garnache-Ottou et 
al., 2007]. It primarily affects the elderly (median age 69 years) [Feuillard et al., 2002]. The 
clinical course is very aggressive and rapidly fatal [Reimer et al., 2003]. Histologically, this 
malignancy is classified as blastic NK-cell lymphoma/leukemia. The 2000 WHO 
classification considers this malignancy as blastic NK-cell lymphoma [Harris et al., 2000]. 
The ontogenic origin of this malignancy has not been clearly identified. Chaperot et al. have 
demonstrated the origin of these tumor cells as dendritic cells [Chaperot et al., 2001]. These 
malignant cells express interleukin-3 (IL-3) receptor maturation with IL-3 and produce 
interferonalpha (IFN-α) in response to influenza virus. These cells become a powerful 
inducer of naïve CD4+ T-cell proliferation and promote T-helper 2 polarization. Finally, 
these authors concluded the origin of this neoplasm is a plasmacytoid dendritic cell subset. 
Feuilliard et al. reported 23 cases with CD4+, CD56+ leukemia. The majority of patients were 
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elderly adults, but three children were included in their report. At diagnosis, most patients 
had cutaneous involvement, with disseminated purple lesions on the dermis. 
Lymphadenopathy and/or splenomegaly were frequent [Chaperot et al., 2001]. 
Morphologic and cytochemical analysis revealed a high frequency of vacuolization with 
pseudopodia-like cytoplasmic expansions. Myeloperoxidase and monocytic esterase activity 
were never detected. 
However, all cases of pDCL do not produce IFN-α and secretion levels of IFN-α have been 
lower than their normal counterparts. pDCL cells proved incapable of differentiating into 
NK cells, B cells, myeloid cells, or monocytes, and differentiation into mature pDC was only 
possible. Furthermore, a subset of pDCL demonstrated the expression of blood dendritic cell 
antigen 2 (BDCA-2), a specific dendritic cell marker. This fact supports that the origin of 
pDCL as dendritic cells [Jaye et al., 2006]. However, some other reports remain 
undetermined concerning the possible origin of pDCL. More investigation is required to 
establish the definitive nature of these CD4+/CD56+ tumor cells. 
2.5.1 Differential diagnosis 
Table 6 shows the differential diagnosis. ENKL is associated with EBV infection, while this 
has not been reported for pDCL. Although expression of CD56+, CD2+, CD7+, and 
intraplasmic granzyme B can be in common between ENKL and pDCL, ENKL never 
expresses CD4+ [Harris et al., 1997]. In about 10% to 20% of acute myelogenous leukemia 
patients, tumor cells express CD33+, CD4+, and CD56+. Very undifferentiated acute 
myelogenous leukemia weakly shows myelocytic or monoblastic markers. In these cases, 
identification of pDC-specific markers (e.g. BDCA-2) is useful [Garnache-Outtu et al., 2007] 
Mixed myeloblastic/NK-cell leukemia are defined as types of myeloid leukemia in the 
WHO 2008 classification [Swerdlow et al., 2008]. These leukemias express CD7+, CD33+, and 
CD56+. They correspond to proliferation of animmature precursor with myeloid and NK 
potential [Suzuki et al., 1997]. The leukemia phenotype is different from pDCL as they do 
not express CD4 and CD36 in reported cases [Suzuki et al., 1997]. Furthermore, in pDCL, 
there is no expression of CD34 , while its expression has always shown in mixed 
myeloblastic/NK-cell leukemia cells. 
 
Marker pDCL ENKL AML Mixed myeloblastic/NK-cell leukemia 
CD2 – + –  
CD7 – + ± + 
CD56 + + + + 
CD4 + – + – 
Granzyme B – +   
CD33 – – + + 
CD117 – – +  
CD34 – – ± + 
CD36 + – – – 
BDCA-2 + – – – 
Abbreviations: AML, acute myelogenous leukemia; BDCA-2, blood dendritic cell antigen 2; ENKL, 
extranodal NK-cell leukemia; pDCL, blastic plasmacytoid dendritic cell neoplasm. 
Table 6. Differential diagnosis of blastic plasmacytoid dendritic cell neoplasms 
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2.5.2 Pediatric cases 
Pediatric pDCL is very rare and limited to a few case reports and small case series. Jegalian 
et al. reported 25 pediatric cases (20 in the literature, 9 at their institution) with pDCL 
[Jegalian et al., 2010]. They demonstrated the clinical features and prognosis of pediatric 
patients. In pediatric patients, 24% of patients lacked cutaneous involvement, which is 
slightly higher rate than adults. In adult patients, pDCL clinical presentation at the time of 
diagnosis usually consists of a cutaneous involvement and the patients without cutaneous 
involvement are very rare. In adult patients, especially the elderly, prognosis is very poor. 
Median OS was only 13 months for all patients. Allogeneic SCT is a useful treatment in 
younger adult patients. They reported a regimen suited to acute lymphoblastic leukemia 
followed by SCT is more effective than using an acute myelogenous leukemia or non-
Hodgkin lymphoma regimen. While the OS of pediatric patients receiving SCT was 67% (4 
of 6 patients), that for patients without SCT was 74%. In pediatric patients, treatment with a 
high-risk regimen appears effective without SCT. SCT was useful for only relapsed or 
secondary remission disease. Outcome of pediatric patients was more favorable than that of 
adults [Jegalian et al., 2010]. 
3. Conclusion 
NK-cell malignancy is difficult to define and there is confusion in diagnosis. One of the 
reasons for the confusion is that CD56 is not only expressed in NK-cell malignancy but in 
various other hematopoietic malignancies, e.g. acute myelogenous leukemia non-Hodgkin 
lymphoma, pDCL. It is hoped that more specific markers for NK-cell malignancy will assist 
in defining these malignancies. NK-cell precursor tumors with lymphomatous presentation 
that expressed NK-specific CD94A1 transcripts have been described [Lin et al., 2005]. I used 
this method and clarified the origin of one case [Hashii et al., 2010]. Antibodies against killer 
immunoglobulin-like receptors (KIRs) will hopefully provide a useful tool for clarification of 
the diagnosis of the NK-cell malignancies. Currently, these antibodies are not commonly 
used. Although, BDCA-2 is useful for clarifying the difference between NK-cell malignancy 
and pDCL, it is not commonly used. The diagnosis of precursor NK-cell lymphoblastic 
leukemia/lymphoma may be considered in cases that express CD56+ along with immature 
T-cell markers (CD2+, CD7+, and CD3ε+) without B-cell or myeloid markers. 
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